Madrigal Pharmaceuticals Inc (MDGL NASDAQ) stock market data APIs
$585.5028
-28.79(-4.9%)
as of December 19, 2025
Try our APIs with
free plan!
Madrigal Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.
Prev. Close
585.5028
Open
556.7125
High
587.8469
Low
556.5426
52 wk Range
265-605
Market Cap
13 423 M
Shares Outstanding
22 711 K
Revenue
741 M
EPS
-4.9555
Beta
-1.046
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Madrigal Pharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Madrigal Pharmaceuticals Inc data using free add-ons & libraries
Get Madrigal Pharmaceuticals Inc Fundamental Data
Madrigal Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 741 M
- EBITDA: -306 007 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-29
- EPS/Forecast: -3.36
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Madrigal Pharmaceuticals Inc News
New
Madrigal Pharmaceuticals (MDGL): Reassessing Valuation After Strong 1‑Year Share Price Surge
Madrigal Pharmaceuticals (MDGL) has quietly turned into one of the stronger performers in biotech, with the stock up roughly 77% over the past year as investors reassess its MASH treatment potential. ...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-asso...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals, Inc. CONSHOHOCKEN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics ...
Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Madrigal Pharmaceuticals, Inc. CONSHOHOCKEN, Pa., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the J.P. Morgan ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
